Integral Diagnostics issues FY26 preliminary guidance, flags revenue of $788–$790 million
AI Market Summary
Integral Diagnostics' preliminary FY26 guidance signals strong operating momentum: revenue up ~25%, operating EBITDA up ~30% with margin expansion, and operating NPAT up ~50%, alongside improved leverage (net debt/EBITDA 2.3x). Capex is in line with guidance, while a new CFO appointment adds near-term execution and transition focus. The update is single-name and sector-specific, limiting broader market spillover.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.46%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Integral Diagnostics has issued preliminary FY26 guidance, forecasting revenue of $788–$790 million, up about 25% year on year. It expects operating EBITDA of $164–$165 million, up around 30%, and operating NPAT of $47–$48 million, up roughly 50%. Diluted operating EPS is projected at 12.5c–12.7c, representing growth of about 23%. Capital expenditure is expected to be $50 million, in line with guidance.
